Portfolio Lab

Smith & Nephew PLC

  • Stock
  • Ticker SNN
  • ISIN US83175M2052
  • NYSE
  • US listing in dollars (ADR)

Health care · Medical technology · United Kingdom

$29.83 0.00%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Smith & Nephew PLC since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

SNNGlobal equities (VT)

$10,000 grew to $13,466. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −55.1% in 09/2022, measured from the peak in 02/2020. The old peak has not been reached again yet.

1-year return
−4.2%
5-year return p.a.
−0.3%
10-year return p.a.
+3.0%
Volatility p.a.
25.5%
Largest decline
−55.1%

Financial statements

Amounts in $ millions from the company's annual financial reports, earnings per share in $ per ordinary share

Fiscal year202020212022202320242025
Income statement
Revenue4,5605,2125,2155,5495,8106,164
Gross profit3,1643,6693,6753,8194,0464,192
Operating income295593450425657794
Net income448524223263412625
Earnings per share51,200.0059,700.000.260.300.470.72
Balance sheet
Total assets11,01210,9209,9669,98710,35410,457
Liabilities5,7335,3524,7074,7705,0895,168
Equity5,2795,5685,2595,2175,2655,289
Cash1,7511,285344300619557
Cash flow
Operating cash flow9358774686089871,285
Capital expenditure-443-408-358-427-381-433
Free cash flow492469110181606852

Annual returns

Best year 2025 at +36.8%, weakest 2022 at −20.2%. 5 of 9 full years were positive. * partial year.

Key metrics

Key figures as of 21 Nov 2026 from the company's latest annual financial report, amounts converted to US dollars at the ECB reference rate. Valuation and market cap appear only where price and earnings per share reliably refer to the same share.

Valuation

Market cap
€12bn
Market cap in trading currency
$13.6bn
Enterprise value
$13.0bn
P/E
21.8
P/S
2.20
P/B
2.56
EV/Sales
2.11
EV/EBITDA
–
Earnings yield
4.6%
FCF yield
6.3%

Results (latest fiscal year)

Revenue
$6.16bn
Gross profit
$4.19bn
EBITDA
–
Net income
$625m
Earnings per share
$0.72
Revenue growth
+6.1%
Earnings growth
+51.7%

Profitability

Gross margin
68.0%
Operating margin
12.9%
Net margin
10.1%
Return on equity
11.8%
Return on assets
6.0%

Balance sheet and cash flow

Cash
$557m
Financial debt
–
Debt/equity %
–
Current ratio
2.57
Book value per share
$6.10
Operating cash flow
$1.29bn
Free cash flow
$852m

Dividend

Dividend yield
2.66%
Dividend (12 months)
$0.79
Yield (12 months)
2.66%
Payout ratio
53%
Ex-dividend date
2 Oct 2026

Shares and trading

Shares outstanding
867m
Volume
1.23m
Avg. volume 3 months
1.56m
Relative volume
0.8

Price and technicals

Price
$29.83
1 day
0.0%
52-week high
$36.90
52-week low
$26.42
Distance to 52-week high
−19.2%
Distance to 52-week low
+12.9%
Distance to 50-day line
+3.0%
Distance to 200-day line
−3.3%
RSI (14)
47
Volatility 1M
32.3%

Performance

1 week
−4.6%
1 month
−3.4%
3 months
+0.7%
6 months
−2.3%
YTD
−9.1%
1 year
−7.6%

Dates

Fiscal year end
31 Dec 2025

Frequently asked questions

How has SNN performed since 11/2016?

$10,000 grew to $13,466 by 20 Nov 2026, which is +3.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is SNN?

Volatility was 25.5% per year, measured on monthly returns. The largest decline from a peak was −55.1%, with the low in 09/2022.

How does SNN compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, SNN returned +3.0% at 25.5%. The correlation of monthly returns was 0.43; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Why does this page show a US listing?

The figures use the stock's depositary receipt (ADR) traded in the US. On individual days its path differs slightly from the price on the home exchange.

Not investment advice. Key figures and financial statements calculated from the company's annual financial reports, without guarantee; key figures converted to US dollars at the ECB reference rate, statements in the currency of the report.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Smith & Nephew PLC (SNN): Return and risk | Portfolio Lab